Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

Metastasis-free survival is a strong surrogate endpoint for overall survival over biochemical failure for men receiving salvage radiotherapy for recurrent prostate cancer

Getty Images

News | Prostate Cancer | November 02, 2020

MFS Is a Strong Surrogate Endpoint for OS for Men Receiving Salvage RT

November 2, 2020 — An analysis of the phase III NRG Oncology clinical trial RTOG 9601 on men receiving salvage...

Conceptual diagram of bio-organizational crushing technology based on high-intensity concentric ultrasonography. Image courtesy of Korea Institue of Science and Technology(KIST)

Conceptual diagram of bio-organizational crushing technology based on high-intensity concentric ultrasonography. Image courtesy of Korea Institue of Science and Technology(KIST)

News | Ultrasound Imaging | November 02, 2020

Destroying Cancer Cells with Non-surgical Ultrasound Treatment

November 2, 2020 — Focusing ultrasound energy on a target site in the body to generate heat can burn and destroy the...

Follow up results on first multicenter trial to report outcomes of salvage low dose radiotherapy brachytherapy after external beam radiotherapy for prostate cancer

News | Prostate Cancer | October 30, 2020

Outcomes of Salvage Low Dose RT Brachytherapy After EBRT for Prostate Cancer

October 30, 2020 — Researchers involved in the phase II NRG Oncology RTOG 0526 trial studying low dose rate (LDR)...

"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20

News | PET Imaging | October 26, 2020

Adding Advanced PET Scans to Radiation Treatment Plans for Prostate Cancer Increases Failure-free Survival Rates

October 26, 2020 — Adding the advanced PET radiotracer fluciclovine to conventional imaging to help guide radiation...

A study from Winship Cancer Institute of Emory University (Winship) has the potential to change how patients whose prostate cancer recurs after prostatectomy are treated. The study will be featured in both the plenary session and press program of the American Society for Radiation Oncology (ASTRO) Annual Meeting on Monday, October 26.

News | Prostate Cancer | October 24, 2020

ASTRO Highlights Winship Study Showing Increased Failure-free Survival in Prostate Cancer

October 24, 2020 — A study from Winship Cancer Institute of Emory University (Winship) has the potential to change how...

The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States

News | Prostate Cancer | October 21, 2020

Quantib Receives FDA Clearance for First-to-Market Prostate Solution

October 21, 2020 — Quantib, a market leader in artificial intelligence solutions for radiology, today announced that it...

Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.

News | Artificial Intelligence | October 20, 2020

Ezra Receives FDA Clearance For Prostate Cancer Artificial Intelligence

October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI...

ASTRO urges radiation oncology benefits management company eviCore to reconsider a move that requires shorter treatment regimens without regard for physician judgement

Getty Images

News | Radiation Oncology | October 02, 2020

Benefits Manager Policy Disrupts Patient-physician Decision Making for Breast and Prostate Cancer Radiation Treatments

October 2, 2020 — Radiation oncologists expressed serious concerns about a new private insurance coverage policy that...

High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020

First U.S. Study Shows Promising Outcomes for High-intensity Focused Ultrasound for Prostate Cancer

September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the...

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020

Artificial Intelligence Identifies Prostate Cancer with Near-perfect Accuracy

July 28, 2020 — A study published in The Lancet Digital Health by UPMC and University of Pittsburgh researchers...

PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

News | PET-CT | July 15, 2020

Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies

July 15, 2020 — Targeted radionuclide therapy has been found to create a favorable tumor microenvironment in prostate...

Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites

News | Prostate Cancer | July 01, 2020

Research Shows Quality of Prostate MRI is Highly Variable Among Institutions

July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for prostate cancer and has...

Maximum-intensity projections, transaxial fusion, and PET images of 18F-PSMA1007 (A-C) and 68Ga-PSMA-11 (D-F) PET/CT scans of 67-y-old patient with GS 8 and PSA 4.9 ng/mL. Marked uptake is seen in urinary bladder and left ureter (arrow) on maximum-intensity projection image of 68Ga-PSMA-11 (D), as opposed to nearly negligible 18F-PSMA-1007 urinary excretion (A). Dominant lesion in left prostatic lobe is evident on both scans (arrowheads). However, second lesion is seen in right lobe only on 18F-PSMA-1007 sc

Maximum-intensity projections, transaxial fusion, and PET images of 18F-PSMA1007 (A-C) and 68Ga-PSMA-11 (D-F) PET/CT scans of 67-y-old patient with GS 8 and PSA 4.9 ng/mL. Marked uptake is seen in urinary bladder and left ureter (arrow) on maximum-intensity projection image of 68Ga-PSMA-11 (D), as opposed to nearly negligible 18F-PSMA-1007 urinary excretion (A). Dominant lesion in left prostatic lobe is evident on both scans (arrowheads). However, second lesion is seen in right lobe only on 18F-PSMA-1007 scan (arrow in C), later verified on pathology as true malignant lesion. Images created by J. Kuten et al., Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.

News | Prostate Cancer | May 12, 2020

Novel Radiotracer Meets Gold Standard for Imaging Prostate Cancer

May 12, 2020 — The novel radiopharmaceutical 18F-PSMA-1007 is both effective and readily available for detecting...

A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

News | Prostate Cancer | March 30, 2020

Managing Prostate Cancer Patients During the COVID-19 Pandemic

March 30, 2020 — In the wake of the COVID-19 pandemic, a team of radiation oncologists from the U.S. and U.K. is...

PSMA PET-CT is a suitable replacement for conventional imaging, providing superior accuracy, to the combined findings of CT and bone scanning

News | Prostate Cancer | March 23, 2020

Prostate Cancer Study Finds Molecular Imaging Could Transform Management of Patients with Aggressive Cancer

March 23, 2020 — Results from a randomised controlled trial involving 300 prostate cancer patients find that a...

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals

News | Radiation Oncology | March 16, 2020

CDC Reports Cancer Death Rates Continue to Decline

March 16, 2020 — The Annual Report to the Nation on the Status of Cancer finds that cancer death rates continued to...

M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers

M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers. (c) University of Maryland Greenebaum Comprehensive Cancer Center

News | Prostate Cancer | March 05, 2020

Adding MRI-targeted Biopsy Leads to More Reliable Diagnosis of Aggressive Prostate Cancer

March 5, 2020 — Using a combination of magnetic resonance imaging (MRI) to target and sample suspicious prostate tissue...

Researchers at Karolinska Institutet in Sweden and Tampere University in Finland have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer

From left: Peter Ström, Martin Eklund, Kimmo Kartasalo, Henrik Olsson och Lars Egevad, researchers at Karolinska Institutet in Sweden. Photo courtesy of Stefan Zimmerman

News | Prostate Cancer | January 20, 2020

AI Can Be Used to Detect and Grade Prostate Cancer

January 20, 2020 — Researchers at Karolinska Institutet in Sweden and Tampere University in Finland have developed a...

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society

News | Radiation Oncology | January 13, 2020

Cancer Mortality Continues Steady Decline, Driven by Progress Against Lung Cancer

January 13, 2020 — The cancer death rate declined by 29 percent from 1991 to 2017, including a 2.2 percent drop from...